

# CleveMed

■ ■ ■ ■ Cleveland Medical Devices Inc.

## **For More Information Contact:**

Maureen Phillips  
Cleveland Medical Devices Inc.  
P: 216.791.6720  
mphillips@clevemed.com  
www.CleveMed.com

## **FOR IMMEDIATE RELEASE**

### **CLEVEMED'S KINESIA DEVICE AWARDED NEUROTECH BUSINESS REPORT'S "GOLD ELECTRODE AWARD" FOR BEST NEW PRODUCT**

CLEVELAND, OHIO (Nov. 20, 2007) – The Neurotech Business Report announced Friday, October 26<sup>th</sup> at the 2007 Neurotech Leaders Forum in Newport Beach, CA that Cleveland Medical Devices Inc.'s (CleveMed) Kinesia™ Quantitative Motor Assessment System would receive the Gold Electrode Award for Best New Product in 2007. Kinesia is a compact wireless patient worn system for quantifying the severity of movement disorders symptoms.

"The Neurotech Reports editors believe the Kinesia product represents a novel and pioneering approach to integrating neurosensing technology with neuromodulation and other therapeutic approaches to treating neurological diseases and disorders," said James Cavuoto, editor and publisher of Neurotech Reports. "We commend CleveMed for their innovation and efficiency in getting a new class of product to market."

The Kinesia system integrates the measurement of electrical muscle activity (EMG) and motion using micro-electrical-mechanical accelerometers and gyroscopes. The device is worn on the wrist and finger while user interface videos guide the patient through upper extremity exercises normally completed in the clinic. Data is wirelessly transmitted to a computer for display, processing and storage. Potential applications include continuous remote monitoring of symptom fluctuations, better tuning of treatment interventions and quantifying motor effects during pharmaceutical development.

"The award punctuates the large clinical market need for technology to quantify and track movement disorder motor symptoms in light of rapidly expanding research and treatment modalities," said Joseph P. Giuffrida, PhD, Director of CleveMed's Division of Movement Disorders. "Kinesia is being developed as a standardized platform to measure motor symptoms. The large population affected by diseases such as Parkinson's and essential tremor may benefit from this technology."

Kinesia was developed through support provided by Small Business Innovation Research grants from the National Institutes of Health, National Institute of Neurological Disorders and Stroke and commercialized with support provided by the Ohio Research Commercialization Grant Program from the State of Ohio.

**About CleveMed** – CleveMed was founded with the goal of developing innovative telemetry devices for a variety of medical applications. Today, CleveMed is developing and

- more -

pioneering the use of novel wireless monitoring systems for high growth neurology and rehabilitation applications, including brain monitoring, sleep disorders and movement disorders. Through these innovations, CleveMed has developed a growing range of products that address the needs of the medical, research and academic communities.

**About Neurotech Reports** - Neurotech Reports, based in San Francisco, CA, is the publisher of Neurotech Business Report, a monthly newsletter covering the neurotechnology industry, and also produces the Neurotech Leaders Forum, a management and investment conference for neurotechnology professionals. For more information, contact Neurotech Reports at [www.neurotechreports.com](http://www.neurotechreports.com).

**-END-**

- more -